Log in

OTCMKTS:STXSStereotaxis Stock Price, Forecast & News

-0.12 (-3.01 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $3.87
50-Day Range
MA: $4.37
52-Week Range
Now: $3.87
Volume195,357 shs
Average Volume312,066 shs
Market Capitalization$267.19 million
P/E RatioN/A
Dividend YieldN/A
Stereotaxis, Inc. designs, manufactures, and markets robotic systems and instruments for the treatment of abnormal heart rhythms in the United States and internationally. Its products include Niobe ES robotic system that enables physicians to complete interventional procedures by providing image guided delivery of catheters and guide wires through the blood vessels and chambers of the heart to treatment sites; and Vdrive system, which offers navigation and stability for the diagnostic and therapeutic devices designed to enhance interventional procedures. The company also offers Odyssey solution, a real-time information solution to manage, control, record, and share procedures across networks. In addition, it provides disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company's disposables and other accessories include V-CAS and V-CAS Deflect catheter advancement systems; and V-loop circular and V-Sono ICE catheter manipulators. The company markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was founded in 1990 and is headquartered in St. Louis, Missouri.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.18 out of 5 stars

Industry, Sector and Symbol

Industry Electromedical equipment
Current SymbolOTCMKTS:STXS
Previous SymbolNASDAQ:STXS



Sales & Book Value

Annual Sales$29.35 million
Cash Flow$0.01 per share
Book Value($0.02) per share


Net Income$120,000.00


Market Cap$267.19 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
-0.12 (-3.01 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STXS News and Ratings via Email

Sign-up to receive the latest news and ratings for STXS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Stereotaxis (OTCMKTS:STXS) Frequently Asked Questions

How has Stereotaxis' stock been impacted by COVID-19 (Coronavirus)?

Stereotaxis' stock was trading at $3.78 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, STXS stock has increased by 2.4% and is now trading at $3.87.
View which stocks have been most impacted by Coronavirus

Do Wall Street analysts recommend investors buy shares of Stereotaxis?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stereotaxis in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Stereotaxis

When is Stereotaxis' next earnings date?

Stereotaxis is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Stereotaxis

How were Stereotaxis' earnings last quarter?

Stereotaxis Inc (OTCMKTS:STXS) posted its earnings results on Thursday, August, 6th. The medical equipment provider reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.02. Stereotaxis had a negative net margin of 14.80% and a negative return on equity of 1,456.01%.
View Stereotaxis' earnings history

What price target have analysts set for STXS?

2 brokers have issued 1-year price objectives for Stereotaxis' stock. Their forecasts range from $6.00 to $9.00. On average, they anticipate Stereotaxis' share price to reach $7.50 in the next year. This suggests a possible upside of 93.8% from the stock's current price.
View analysts' price targets for Stereotaxis

Has Stereotaxis been receiving favorable news coverage?

Media headlines about STXS stock have been trending very positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stereotaxis earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Stereotaxis

Who are some of Stereotaxis' key competitors?

What other stocks do shareholders of Stereotaxis own?

Who are Stereotaxis' key executives?

Stereotaxis' management team includes the following people:
  • Mr. David Leo Fischel C.F.A., CFA, CPA, CEO & Chairman (Age 32)
  • Mr. Martin C. Stammer, Chief Financial Officer (Age 39)
  • Mr. Kevin M. Barry, Chief Legal Officer, Corp. Sec. & Chief Compliance Officer
  • Dr. Gery Tomassoni M.D., FHRS, Chief Medical Officer
  • Dr. J. David Burkhardt, Chief Devel. Advisor

What is Stereotaxis' stock symbol?

Stereotaxis trades on the OTCMKTS under the ticker symbol "STXS."

Who are Stereotaxis' major shareholders?

Stereotaxis' stock is owned by a number of institutional and retail investors. Top institutional investors include UBS Group AG (0.45%), Roubaix Capital LLC (0.36%), Sturgeon Ventures LLP (0.30%), New York State Common Retirement Fund (0.06%), SG Americas Securities LLC (0.03%) and State Board of Administration of Florida Retirement System (0.02%). Company insiders that own Stereotaxis stock include David Benfer and Paul J Isaac.
View institutional ownership trends for Stereotaxis

Which major investors are buying Stereotaxis stock?

STXS stock was bought by a variety of institutional investors in the last quarter, including Roubaix Capital LLC, UBS Group AG, Sturgeon Ventures LLP, New York State Common Retirement Fund, SG Americas Securities LLC, State Board of Administration of Florida Retirement System, Virtu Financial LLC, and Eidelman Virant Capital.
View insider buying and selling activity for Stereotaxis

How do I buy shares of Stereotaxis?

Shares of STXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stereotaxis' stock price today?

One share of STXS stock can currently be purchased for approximately $3.87.

How big of a company is Stereotaxis?

Stereotaxis has a market capitalization of $267.19 million and generates $29.35 million in revenue each year. Stereotaxis employs 119 workers across the globe.

What is Stereotaxis' official website?

The official website for Stereotaxis is www.stereotaxis.com.

How can I contact Stereotaxis?

Stereotaxis' mailing address is 4320 FOREST PARK AVENUE SUITE 100, ST.LOUIS MO, 63108. The medical equipment provider can be reached via phone at 314-678-6100 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.